273 related articles for article (PubMed ID: 32349222)
1. Tubulin Resists Degradation by Cereblon-Recruiting PROTACs.
Gasic I; Groendyke BJ; Nowak RP; Yuan JC; Kalabathula J; Fischer ES; Gray NS; Mitchison TJ
Cells; 2020 Apr; 9(5):. PubMed ID: 32349222
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the cereblon-recruiting tubulin PROTACs effective in overcoming Taxol resistance in vitro and in vivo.
Yang H; Qin J; Pei Y; Guan S; Zhao M; Wang Y; Yao Y; Duan Y; Sun M
Eur J Med Chem; 2024 Feb; 265():116067. PubMed ID: 38171146
[TBL] [Abstract][Full Text] [Related]
3. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
4. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
[TBL] [Abstract][Full Text] [Related]
6. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
7. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
[TBL] [Abstract][Full Text] [Related]
9. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
10. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
11. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
12. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
13. Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1.
Meyers M; Cismoski S; Panidapu A; Chie-Leon B; Nomura DK
ACS Chem Biol; 2024 Jan; 19(1):58-68. PubMed ID: 38192078
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.
Kabir M; Qin L; Luo K; Xiong Y; Sidi RA; Park KS; Jin J
J Med Chem; 2024 Apr; 67(8):6880-6892. PubMed ID: 38607318
[TBL] [Abstract][Full Text] [Related]
15. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
16. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
17. Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation.
Donoghue C; Cubillos-Rojas M; Gutierrez-Prat N; Sanchez-Zarzalejo C; Verdaguer X; Riera A; Nebreda AR
Eur J Med Chem; 2020 Sep; 201():112451. PubMed ID: 32634680
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
[TBL] [Abstract][Full Text] [Related]
19. A Degron Blocking Strategy Towards Improved CRL4
Bouguenina H; Scarpino A; O'Hanlon JA; Warne J; Wang HZ; Wah Hak LC; Sadok A; McAndrew PC; Stubbs M; Pierrat OA; Hahner T; Cabry MP; Le Bihan YV; Mitsopoulos C; Sialana FJ; Roumeliotis TI; Burke R; van Montfort RLM; Choudhari J; Chopra R; Caldwell JJ; Collins I
Chembiochem; 2023 Dec; 24(23):e202300351. PubMed ID: 37418539
[TBL] [Abstract][Full Text] [Related]
20. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]